F7 encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in F7 can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides.

The Abbkine Cleaved-Factor VII LC (R212) Rabbit Polyclonal Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen anddetects endogenous levels of fragment of activated Factor VII LC protein resulting from cleavage adjacent to R212. The antibody has been validaed in WB, IHC-P, ELISA and reacts with Human samples.

Abbkine supplies below price/size: $100/30μl, $220/100μl, $360/200μl of Rabbit Anti-Cleaved-Factor VII LC (R212) Polyclonal Antibody at https://www.abbkine.com/product/cleaved-factor-vii-lc-r212-polyclonal-antibody-abp50059.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.